Novavax

Novavax dropped sharply in regular trading, closing at $8.42, down 5.5%, driven by a 79% YoY plunge in Q1 revenue to $139.5 million and a swing to a net loss of $9.5 million from Q4 profit. The stock slid from its open of $8.84 to hit an intraday low of $8.42, with post-market trading holding near that level. Volume reached 3.75 million shares, reflecting a turnover rate of 2.65%. The stock now sits 29.66% below its 52-week high of $11.97, with YTD gains trimmed to 18.09%, and has closed below both its 20-day ($9.18) and 60-day ($9.14) moving averages. While the weak earnings and bearish technicals weigh, the upcoming Jefferies Global Healthcare Conference may fuel discussions on COVID vaccine updates.

Novavax fell 5.07% to close at $8.855 amid a volatile session, primarily driven by a sharp Q1 2026 earnings reversal: net income swung from a profit of $17.5 million in Q4 2025 to a loss of $9.5 million, with EPS at -$0.0581, down 101.98% year-over-year, and revenue dropping 79.07% to $139.5 million. The stock touched a pre-market high of $9.36 before opening lower and sliding steadily to an intraday low of $8.855, staying below both its 20-day MA of $9.199 and 60-day MA of $9.143. Despite the weak session, the stock is still up 24.19% year-to-date, though it remains 26.02% below its 52-week high of $11.97. Ongoing developments, including Shah Capital's opposition to management and the Sanofi partnership, and the FDA advisory committee's review of updated COVID-19 vaccines, continue to be monitored by investors.

Novavax fell 4.0% to $9.35 today, driven by a 79% year-over-year plunge in Q1 revenue to $139.5 million and a swing to a net loss of -$9.5 million (EPS -$0.0581 vs $3.14 a year ago). The stock opened at $9.56, nearly 2% below the prior close of $9.74, and hit an intraday low of $9.135 before recovering modestly; the session high of $9.56 was well below the pre-market peak of $9.792. Post-market weakness continued at $9.35. Despite a YTD gain of 31.14%, the stock is now 21.89% below its 52-week high of $11.97 and trades near its MA60 of $9.067. On the positive side, Novavax secured an invitation to the Jefferies 2026 healthcare conference, and FDA advisors are considering updating COVID-19 vaccines to target the XFG variant for the 2026-27 season, which could drive future demand.

Novavax shares surged 5.13% during the regular session to close at $9.945, gapping up after pre-market strength and accelerating on rising volume. The move followed a recovery on June 30 from six consecutive sessions of decline. Q1 2026 revenue fell 79% YoY to $139.5M, and EPS turned negative, yet the market focused on the upcoming Jefferies Global Healthcare Conference participation and FDA advisers' review of targeting the XFG variant for the 2026-27 COVID vaccine. Year-to-date, the stock has gained 39.48% from its start of $7.13, and now trades above its MA20 ($9.15) and MA60 ($9.055), though 16.92% below the 52-week high of $11.97. Meanwhile, Shah Capital Management voted against multiple proposals on the June 18 ballot, highlighting governance tensions.